Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
about
Preclinical mouse cancer models: a maze of opportunities and challenges.PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelEngineering cancer microenvironments for in vitro 3-D tumor models.Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis."Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts.Noninvasive Evaluation of Metabolic Tumor Volume in Lewis Lung Carcinoma Tumor-Bearing C57BL/6 Mice with Micro-PET and the Radiotracers 18F-Alfatide and 18F-FDG: A Comparative Analysis.Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer.COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomyStereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model.EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Mouse models in the era of large human tumour sequencing studies
P2860
Q27322080-68FB22EA-8975-412C-8AC2-C46933F4F587Q27327191-7BEAC4CE-7086-4F13-836B-C50D919B44ADQ30358020-C68E0FC4-F46F-45D4-BA6B-35B329EA5575Q33761491-D7CB3C27-2258-4B78-8E9B-B60BAE2205C3Q34450094-02DDDCC6-625A-4CF2-AC24-74982A0582DAQ35767740-C5A19260-06DC-4C95-B7F9-380A17785AB4Q37398345-9A65522D-A184-4FFE-A4BC-4DCCF06683DDQ38981326-FEB93092-6E84-463C-B3E4-3F916B8436B1Q38994266-93DD576A-CA71-4411-ABB2-5A6C943CC530Q41766834-75C188BA-AA95-4423-B425-62385A60830FQ44323391-C46C2F56-CD86-4C39-9FE7-B5DE253C8C4BQ44456046-3C7B720B-99DF-440B-8A54-73162BC8B7F0Q58776633-1DBC2F36-316D-463B-988F-C4392BA7B403
P2860
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Preclinical therapeutic respon ...... om its primary tumor of origin
@ast
Preclinical therapeutic respon ...... om its primary tumor of origin
@en
type
label
Preclinical therapeutic respon ...... om its primary tumor of origin
@ast
Preclinical therapeutic respon ...... om its primary tumor of origin
@en
prefLabel
Preclinical therapeutic respon ...... om its primary tumor of origin
@ast
Preclinical therapeutic respon ...... om its primary tumor of origin
@en
P2093
P2860
P356
P1476
Preclinical therapeutic respon ...... om its primary tumor of origin
@en
P2093
Carrie Bonomi
Chi-Ping Day
Glenn Merlino
John Carter
Melinda Hollingshead
P2860
P304
P356
10.1002/IJC.25978
P577
2011-04-20T00:00:00Z